Tdap Vaccine Effectiveness in Adolescents During the 2012 Washington State Pertussis Epidemic

Anna M. Acosta, MDa,b, Chas DeBolt, RN, MPHc, Azadeh Tasslimi, MPHd, Melissa Lewis, MPHd, Laurie K. Stewart, MSf, Lara K. Misegades, PhD, MSb, Nancy E. Messonnier, MDg, Thomas A. Clark, MD, MPHh, Stacey W. Martin, MSi, Manisha Patel, MD, MSb

abstract

BACKGROUND: Acellular pertussis vaccines replaced whole-cell vaccines for the 5-dose childhood vaccination series in 1997. A sixth dose of pertussis-containing vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap), was recommended in 2005 for adolescents and adults. Studies examining Tdap vaccine effectiveness (VE) among adolescents who have received all acellular vaccines are limited.

METHODS: To assess Tdap VE and duration of protection, we conducted a matched case-control study during the 2012 pertussis epidemic in Washington among adolescents born during 1993–2000. All pertussis cases reported from January 1 through June 30, 2012, in 7 counties were included; 3 controls were matched by primary provider clinic and birth year to each case. Vaccination histories were obtained through medical records, the state immunization registry, and parent interviews. Participants were classified by type of pertussis vaccine received on the basis of birth year: a mix of whole-cell and acellular vaccines (1993–1997) or all acellular vaccines (1998–2000). We used conditional logistic regression to calculate odds ratios comparing Tdap receipt between cases and controls.

RESULTS: Among adolescents who received all acellular vaccines (450 cases, 1246 controls), overall Tdap VE was 63.9% (95% confidence interval [CI]: 50% to 74%). VE within 1 year of vaccination was 73% (95% CI: 60% to 82%). At 2 to 4 years postvaccination, VE declined to 34% (95% CI: −0.03% to 58%).

CONCLUSIONS: Tdap protection wanes within 2 to 4 years. Lack of long-term protection after vaccination is likely contributing to increases in pertussis among adolescents.

WHAT'S KNOWN ON THIS SUBJECT: Although waning immunity with the childhood pertussis vaccination series has been reported, there are limited data on duration of protection of the adolescent pertussis vaccine (Tdap), especially among those who have received only acellular vaccines.

WHAT THIS STUDY ADDS: This study reports that protection from Tdap wanes substantially 2 to 4 years after vaccination among adolescents who received all acellular vaccines during childhood. This waning protection is likely contributing to the increase in adolescent pertussis.

Epidemic Intelligence Service, Scientific Education and Professional Development Program Office, *Meningitis and Vaccine Preventable Disease Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, and †Biostatistics Office, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and ‡Communicable Disease Epidemiology, Washington State Department of Health, Shoreline, Washington

Dr Acosta led the conceptualization and design of the study, oversaw the data collection, performed data analyses, interpreted the data, drafted the initial manuscript, and finalized the final draft; Ms DeBolt assisted with data collection and interpretation and provided critical revision of the manuscript for important intellectual content; Ms Tasslimi assisted with data collection, analyses, and interpretation and provided critical revision of the manuscript for important intellectual content; Ms Lewis assisted with data collection and analyses and provided critical revision of the manuscript for important intellectual content; Ms Stewart assisted with data collection and provided critical revision of the manuscript for important intellectual content; Dr Misegades contributed to the study design and data interpretation and provided critical revision of the manuscript for important intellectual content; Dr. Messonnier contributed to the conceptualization of the study and data interpretation and provided critical revision of the manuscript for important intellectual content; Dr Clark contributed to the conceptualization of the study and data interpretation and provided critical revision of the manuscript for important intellectual content;
Despite high childhood and adolescent vaccination coverage, >48,000 pertussis cases were reported in the United States in 2012, the greatest number reported since 1955. In addition, there were new and concerning changes in the age distribution of pertussis cases, with increasing incidence among fully vaccinated children and adolescents within a few years of vaccination. 

Although infants <1 year of age continue to have the highest rates of pertussis, increased rates among 7- to 10-year-olds were recently observed. Notably, this cohort of children was among the first to receive solely acellular pertussis vaccines for the childhood series. Waning immunity after vaccination with diphtheria-tetanus-acellular pertussis (DTaP) vaccines appears to be a major contributing factor for increased disease risk. 

Because tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap) was recommended for adults and adolescents only in 2006, studies estimating Tdap vaccine effectiveness (VE) and duration of protection are few. Several observational studies noted an overall VE range of 64% to 78% within 2 years of vaccination. To our knowledge, only 1 study has measured Tdap duration of protection for >2 years, and it concluded that VE waned over time. 

In 2012, Washington State declared a pertussis epidemic with nearly 5000 cases reported. An unexpectedly high disease incidence was seen in adolescents 13 to 14 years of age despite Tdap coverage of 86%. The emergence of disease in this age group had not been observed since the introduction of Tdap, raising concerns for waning immunity after the Tdap dose in adolescents who received all acellular pertussis vaccines as children. The epidemic in Washington provided an opportunity to estimate Tdap VE and duration of protection among the first cohort of adolescents who received all acellular vaccines.

**METHODS**

**Study Oversight**

This evaluation was conducted as part of the public health response to the 2012 Washington pertussis epidemic and was determined to be nonresearch program evaluation by the Centers for Disease Control and Prevention Human Research Protection Office and the Washington State Department of Social and Health Services Institutional Review Board.

**Study Design and Population**

To estimate Tdap VE and duration of protection, we conducted a matched case-control study. The 7 Washington counties reporting >50 cases among adolescents during the study period of January 1 to June 30, 2012, agreed to participate (Clark, King, Pierce, Skagit, Snohomish, Yakima, and Whatcom).

The study included adolescents 11 to 19 years of age, born from January 1, 1993, through December 31, 2000. We included all suspected, probable, and confirmed pertussis cases reported among residents of the 7 participating counties during the study period. Cases were classified by using the Council of State and Territorial Epidemiologists case definitions for probable and confirmed pertussis cases. A clinical case was defined as cough for ≥14 days with at least 1 of the following symptoms: whoop, posttussive vomiting, or paroxysmal cough. A confirmed case was defined as cough illness of any duration plus isolation of Bordetella pertussis from a clinical specimen or a clinical case with either a positive polymerase chain reaction test result or contact with a laboratory-confirmed case (epidemiologic link). Clinical cases that were not laboratory-confirmed or epidemiologically linked to a laboratory-confirmed case were classified as probable cases. The Washington State Department of Health also included a suspected case category defined as a positive polymerase chain reaction test result with illness not meeting the clinical case definition.

We selected 3 controls for each case, matched by birth year and primary provider clinic. Controls were randomly selected from a clinic-generated patient roster that included all adolescents born in the same year as the case and who had at least 1 clinic visit since 2005. Potential controls were excluded and replaced with another randomly selected control if the provider suspected or diagnosed pertussis during the study period, the patient had been discharged from the clinic, the patient had an out-of-state home zip code, or patient medical records were unavailable. The symptom onset date of the case was used as the enrollment date for each case and associated matched controls.

Demographic information (date of birth, gender, home zip code, ethnicity, race) and vaccination histories for cases and controls were collected at provider clinics by using a standardized protocol and medical chart abstraction form. Vaccination date, product, manufacturer, and lot number were recorded for all documented pertussis-, diphtheria-, or tetanus-containing vaccines, including the childhood series and adolescent dose when available. To verify brand, we matched available lot numbers for the childhood series and adolescent dose with known lot numbers provided by the Washington State Department of Health and 2 pertussis vaccine manufacturers (GlaxoSmithKline, Brentford, United Kingdom; Sanofi Pasteur, Swiftwater, PA).

We supplemented provider vaccination histories with information from the Washington State Immunization Information...
Tdap receipt was confirmed in the provider records, the immunization registry, or by parent interview. We classified participants as unvaccinated if no record of Tdap vaccination date was found in the provider records or the immunization registry and Tdap nonreceipt was confirmed by a parent. In addition, participants were classified as unvaccinated if Tdap receipt was confirmed but the vaccination occurred after the enrollment date or if Tdap was received within 2 weeks before the enrollment date. We considered a participant’s vaccination status to be unknown if a Tdap vaccination date was not documented in the provider records or the immunization registry and the parent interview was inconclusive.

The Washington State Childhood Vaccination Program has been the sole distributor of childhood and adolescent vaccines to public and private health care providers since the early 1990s.17,18 We reviewed available vaccine distribution data and determined that the transition of whole-cell to acellular pertussis vaccines for the complete childhood series occurred during 1997, after which we assumed that whole-cell vaccines were no longer available. We verified this assumption by cross-checking study-obtained lot numbers against manufacturer data.

To evaluate the impact of the whole-cell or acellular pertussis childhood vaccination series on Tdap VE, study participants were stratified on the basis of birth year into 2 groups. The acellular group included adolescents born from 1998 to 2000 and were assumed to have received all acellular pertussis vaccines for the childhood series, whereas the mixed group included those born from 1993 to 1997 and were assumed to have received a mix of whole-cell and acellular pertussis vaccines.

**Statistical Analysis**

To estimate the association between pertussis and Tdap receipt, we used conditional logistic regression to calculate odds ratios, accounting for matching factors (provider and birth year). VE was calculated as: $1 - \text{odds ratio} \times 100\%$. Tdap-unvaccinated participants were the reference group in all models. We estimated duration of protection by measuring the association between pertussis and time since Tdap vaccination (<12 months, 12–23 months, 24–47 months).

We excluded cases and controls if Tdap vaccination status was unknown, or if there was documentation of inadvertent administration of DTaP during adolescence, Tdap before the age of 10 years, or ≥2 Tdap doses. In addition, controls were excluded if they had ever been reported to the Washington State Department of Health as having pertussis.

The primary analysis measured Tdap VE and duration of protection in study participants who received all acellular pertussis vaccines for the childhood series (birth years 1998–2000; ages 11–14 years).

Additional subgroup analyses assessed the stability of the VE estimates by restricting the analysis to those with confirmed and probable case status, those with confirmed case status only, or those with a complete and on-schedule childhood series. We also evaluated Tdap VE among participants who received a mix of whole-cell and acellular vaccines (birth years 1993–1997; ages 15–19 years), as well as differences in VE by Tdap product.

Statistical comparison of demographic characteristics between cases and controls was performed by using conditional logistic regression. We evaluated trends in Tdap vaccine status by birth year using the Cochran-Armitage test. All analyses were conducted in SAS software, version 9.3 (SAS Institute, Cary, NC).

**RESULTS**

During the study period, 1153 pertussis cases among adolescents were reported in Washington. Of those, 959 were reported in the 7 participating counties, representing 83% of all Washington adolescent cases and 73% of all Washington providers reporting adolescent cases. Pertussis incidence for this age group was 182.3 per 100,000 persons during the study period.

Data were collected for 887 cases and 2599 matched controls. Data were not collected for 72 cases for the following reasons: a provider was not available for the patient ($n = 45; 63.4\%$), the provider refused to participate ($n = 14; 19.7\%$), or the provider was located outside the participating counties ($n = 12; 16.9\%$). An additional 51 cases (5.8\%) and 277 controls (10.7\%) were excluded from the analysis (Table 1). The final analysis included 836 cases and 2322 controls. Of the 836 cases, 656 (78.5\%) were classified as confirmed, 92 (11.0\%) as probable, and 88 (10.5\%) as suspect.
Table 2 lists demographic and vaccine characteristics of the cases and controls included in the analysis. The median age among study participants was 14 years; 54% were born between 1998 and 2000. Cases were more likely to be white (P = .003) and non-Hispanic (P = .03) than controls; however, a substantial amount of race and ethnicity data was not documented in the medical records and therefore was unknown. Although 74% of cases and 75% of controls had 5 documented doses for the childhood series, only 60% of cases and 58% of controls had a 5-dose series that was on schedule. Brand was identified by lot number for 25% to 29% of the childhood doses administered, depending on the dose number. Although documentation of childhood series lot numbers was limited, all childhood vaccines administered in study participants during 1998 or later with available lot numbers were confirmed to be acellular pertussis vaccines.

Eighty-one percent of cases and 90% of controls were vaccinated with Tdap, and both had similar ages at vaccination and time since vaccination. Overall, >84% of study participants were vaccinated with Tdap at the recommended ages of 11 to 12 years.

For the primary analysis, which included only those who received acellular vaccines for the primary series (450 cases, 1246 controls), the overall Tdap VE estimate against pertussis was 63.9% (95% confidence interval [CI]: 49.7% to 74.1%) (Table 3). When these participants were stratified by time since Tdap vaccination, the VE within 12 months was 73.1% (95% CI: 60.3% to 81.8%). At 12 to 23 months postvaccination, the VE estimate was 54.9% (95% CI: 32.4% to 70.0%), and by 24 to 47 months it was 34.2% (95% CI: −0.03% to 58.0%). Subgroup analyses limited to confirmed cases or those with on-schedule childhood vaccinations were not substantially different from the primary analysis, with overlapping CIs noted (Fig 1, Supplemental Tables 5 and 6). Similarly, a subgroup analysis excluding those with suspect case status was not notably different from the primary analysis (data not shown).

The overall Tdap VE for the mixed-vaccine group (386 cases, 1076 controls) was 51.5% (95% CI: 26.1% to 68.1%). Because the mixed group was heavily weighted toward participants who received Tdap at least 3 years before study enrollment (Fig 2), Tdap duration of protection was stratified by less or more than 4 years since vaccination. The VE estimates for each of these time points were similar to the overall VE.
There was a greater proportion of participants with unknown Tdap vaccination status in the mixed group compared with the acellular group (7.2% vs 4.5%, respectively; \( P = .0007 \)), and a significant trend of increasing unknown Tdap vaccination status with increasing age (Cochran-Armitage trend test, \( z = -6.04, P < .0001 \)).

The Tdap product (Boostrix; GlaxoSmithKline; Adacel; Sanofi Pasteur) was verified by lot number in 76% of recipients (Table 2). Cases were more likely to have been vaccinated with Adacel compared with controls \( (P = .05) \), despite Adacel being used less frequently than Boostrix \((17\% \text{ vs } 59\%), \text{ respectively})

Analyses of VE estimates by product were stratified by vaccine group. Regardless of group analyzed, Boostrix had slightly higher effectiveness than Adacel, although CIs overlapped (Table 4). Product-specific VE estimates in the mixed group were slightly lower than in the acellular group, but CIs again overlapped.

**DISCUSSION**

Tdap was recommended in the early 2000s to address the burden of pertussis among adolescents and adults.\(^{19}\) The preferred administration age of 11 to 12 years targeted the peak of disease in adolescence and supported the established adolescent vaccination platform. Among adolescents, national Tdap vaccine uptake has increased steadily after its introduction, and early evaluations indicated it was effective in reducing the adolescent disease burden.\(^{20-22}\) However, it is notable that the group of adolescents who initially received Tdap also received whole-cell vaccines during childhood. Despite promising indicators, the number of pertussis cases among adolescents has climbed during 2012, mainly in 13- to 14-year-olds who received solely acellular vaccines.\(^{3}\) We have found that among adolescent recipients of all acellular vaccines, overall Tdap VE is 64%, with substantial waning of protection after 2 years. Although the study methodology differed substantially, our results were consistent with a recent Tdap VE study in Wisconsin.\(^{11}\) The waning protection revealed in both studies indicates that it likely is a major contributor to the increasing pertussis incidence in this age group.

Although an initial study aim was to compare Tdap VE between adolescents who received a mix of whole-cell and acellular vaccines with those who received all acellular
vaccines, this was not possible due to the difference in time since vaccination between the groups.

Seventy-seven percent of adolescents in the mixed-vaccine group received Tdap at least 3 years before study enrollment in comparison with only 4% in the acellular vaccine group. Of note, however, was the finding that VE estimates in the mixed-vaccine group at less or more than 4 years since Tdap vaccination were similar (51.5% vs 52.2%). This finding suggests that durability of protection after Tdap is limited regardless of type of vaccines received during childhood, but that the rate of waning may be higher in those vaccinated solely with acellular vaccines.

Reasons for more rapid waning of Tdap-induced protection in persons vaccinated with acellular pertussis vaccines may be related to the immunologic response to acellular vaccines and a potential limitation of acellular vaccines to prevent transmission. Both whole-cell and acellular vaccines elicit pertussis-specific antibodies, which decrease after immunization. However, other immunologic mechanisms, such as cell-mediated immunity, have also been associated with protection against pertussis disease and may be suboptimal after vaccination with acellular vaccines. In addition, recent data from a novel nonhuman primate model showed that although acellular vaccines prevented symptomatic disease, they failed to prevent infection and transmission.

Recently observed genetic variation in pertussis strains may also be playing a role in VE. In particular, the rapid emergence of pertactin-deficient pertussis strains is concerning, because pertactin is one of the major antigenic components of acellular pertussis vaccines. A recent evaluation of available isolates obtained during the Washington 2012 outbreak revealed that over half carried a particular mutation resulting in pertactin deficiency. Because our study was not designed to measure VE against these emerging strains, further evaluation is needed.

Analysis of Tdap product revealed a trend toward slightly higher VE estimates with Boostrix as opposed to Adacel, regardless of vaccine group analyzed. However, CIs overlapped between Tdap product and between vaccine group. On the basis of this analysis, definitive conclusions cannot be drawn regarding specific Tdap product effectiveness; nevertheless, these trends mirror findings of the Wisconsin study, which showed higher VE with Boostrix.

As with all case-control studies, unaddressed biases could influence our findings. The likelihood and timing of Tdap receipt are strongly correlated with age; to control for this potential bias, we matched on birth year. We also matched on primary provider clinic in an attempt to control for differences in provider.

Table 4: Estimated Tdap VE Against Pertussis, by Brand and Vaccine Group

<table>
<thead>
<tr>
<th></th>
<th>Cases</th>
<th>Controls</th>
<th>Odds Ratio (95% CI)</th>
<th>Estimated VE (95% CI), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>All birth years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>836</td>
<td>2322</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Tdap-unvaccinated</td>
<td>162</td>
<td>229</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Boostrix</td>
<td>387</td>
<td>1245</td>
<td>0.40 (0.30 to 0.52)</td>
<td>60.1 (47.7 to 69.6)</td>
</tr>
<tr>
<td>Adacel</td>
<td>136</td>
<td>342</td>
<td>0.51 (0.37 to 0.71)</td>
<td>48.3 (28.8 to 63.2)</td>
</tr>
<tr>
<td>Unknown brand</td>
<td>151</td>
<td>506</td>
<td>0.37 (0.27 to 0.50)</td>
<td>63.2 (49.9 to 73.0)</td>
</tr>
<tr>
<td>Acellular vaccine group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(birth years 1998–2000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>450</td>
<td>1256</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Tdap-unvaccinated</td>
<td>109</td>
<td>154</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Boostrix</td>
<td>231</td>
<td>725</td>
<td>0.37 (0.27 to 0.53)</td>
<td>62.6 (47.4 to 73.4)</td>
</tr>
<tr>
<td>Adacel</td>
<td>50</td>
<td>129</td>
<td>0.44 (0.29 to 0.71)</td>
<td>55.7 (29.3 to 72.2)</td>
</tr>
<tr>
<td>Unknown brand</td>
<td>60</td>
<td>238</td>
<td>0.27 (0.17 to 0.42)</td>
<td>73.3 (58.5 to 82.8)</td>
</tr>
<tr>
<td>Mixed-vaccine group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(birth years 1993–1997)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>386</td>
<td>1076</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Tdap-unvaccinated</td>
<td>53</td>
<td>75</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Boostrix</td>
<td>156</td>
<td>520</td>
<td>0.44 (0.28 to 0.68)</td>
<td>56.5 (31.7 to 72.3)</td>
</tr>
<tr>
<td>Adacel</td>
<td>86</td>
<td>213</td>
<td>0.61 (0.37 to 0.99)</td>
<td>39.2 (0.04 to 62.8)</td>
</tr>
<tr>
<td>Unknown brand</td>
<td>91</td>
<td>288</td>
<td>0.49 (0.31 to 0.78)</td>
<td>50.6 (22.2 to 68.7)</td>
</tr>
</tbody>
</table>
A cost-effectiveness analysis assumed lower burden of disease in short duration of protection and the significance of a second dose of Tdap, modeling a best-case scenario of VE and duration of protection, revealed only a small reduction in the number of cases while incurring very high costs. For these reasons, in addition to the challenges of improving adult vaccination coverage, the Advisory Committee on Immunization Practices has not supported a recommendation for additional Tdap doses for the general population. In the interim, efforts to protect infants, who are at highest risk of critical disease and death, should be prioritized by reinforcing the recent recommendation for Tdap use during each pregnancy.

CONCLUSIONS
We showed that Tdap protection is unlikely to result in significant disease reduction given its short duration of protection and the assumed lower burden of disease in adults. A cost-effectiveness analysis of a second dose of Tdap, modeling a best-case scenario of VE and duration of protection, revealed only a small reduction in the number of cases while incurring very high costs. For these reasons, in addition to the challenges of improving adult vaccination coverage, the Advisory Committee on Immunization Practices has not supported a recommendation for additional Tdap doses for the general population. In the interim, efforts to protect infants, who are at highest risk of critical disease and death, should be prioritized by reinforcing the recent recommendation for Tdap use during each pregnancy.

CONCLUSIONS
We showed that Tdap protection is unlikely to result in significant disease reduction given its short duration of protection and the assumed lower burden of disease in adults. A cost-effectiveness analysis of a second dose of Tdap, modeling a best-case scenario of VE and duration of protection, revealed only a small reduction in the number of cases while incurring very high costs. For these reasons, in addition to the challenges of improving adult vaccination coverage, the Advisory Committee on Immunization Practices has not supported a recommendation for additional Tdap doses for the general population. In the interim, efforts to protect infants, who are at highest risk of critical disease and death, should be prioritized by reinforcing the recent recommendation for Tdap use during each pregnancy.

CONCLUSIONS
We showed that Tdap protection is unlikely to result in significant disease reduction given its short duration of protection and the assumed lower burden of disease in adults. A cost-effectiveness analysis of a second dose of Tdap, modeling a best-case scenario of VE and duration of protection, revealed only a small reduction in the number of cases while incurring very high costs. For these reasons, in addition to the challenges of improving adult vaccination coverage, the Advisory Committee on Immunization Practices has not supported a recommendation for additional Tdap doses for the general population. In the interim, efforts to protect infants, who are at highest risk of critical disease and death, should be prioritized by reinforcing the recent recommendation for Tdap use during each pregnancy.

CONCLUSIONS
We showed that Tdap protection is unlikely to result in significant disease reduction given its short duration of protection and the assumed lower burden of disease in adults. A cost-effectiveness analysis of a second dose of Tdap, modeling a best-case scenario of VE and duration of protection, revealed only a small reduction in the number of cases while incurring very high costs. For these reasons, in addition to the challenges of improving adult vaccination coverage, the Advisory Committee on Immunization Practices has not supported a recommendation for additional Tdap doses for the general population. In the interim, efforts to protect infants, who are at highest risk of critical disease and death, should be prioritized by reinforcing the recent recommendation for Tdap use during each pregnancy.

ACKNOWLEDGMENTS
We acknowledge the Washington State Department of Health and the local health jurisdictions of Clark, King, Pierce, Skagit, Snohomish, Yakima, and Whatcom counties for their leadership and strong support of this study. We also thank the members of the Epi-Aid team for successfully completing the important task of data collection in a very short time period.

Funding: No external funding.

Kicking off the discussion, the report highlights the importance of Tdap vaccination, especially for infants, who are at the highest risk of critical disease and death. The interim recommendation for Tdap use during each pregnancy is reinforced as critical. The analysis concludes with an urgent call for policies to protect infants, emphasizing the need for continued and enhanced vaccination efforts.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

The financial relationships relevant to this article to disclose are not indicated.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

The financial relationships relevant to this article to disclose are not indicated.
REFERENCES


Tdap Vaccine Effectiveness in Adolescents During the 2012 Washington State Pertussis Epidemic

Anna M. Acosta, Chas DeBolt, Azadeh Tasslimi, Melissa Lewis, Laurie K. Stewart, Lara K. Misegades, Nancy E. Messonnier, Thomas A. Clark, Stacey W. Martin and Manisha Patel

Pediatrics; originally published online May 4, 2015;
DOI: 10.1542/peds.2014-3358

Updated Information & Services
including high resolution figures, can be found at:
/content/early/2015/04/28/peds.2014-3358

Supplementary Material
Supplementary material can be found at:
/content/suppl/2015/04/28/peds.2014-3358.DCSupplemental.html

Citations
This article has been cited by 15 HighWire-hosted articles:
/content/early/2015/04/28/peds.2014-3358#related-urls

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml
Tdap Vaccine Effectiveness in Adolescents During the 2012 Washington State Pertussis Epidemic
Anna M. Acosta, Chas DeBolt, Azadeh Tasslimi, Melissa Lewis, Laurie K. Stewart, Lara K. Misegades, Nancy E. Messonnier, Thomas A. Clark, Stacey W. Martin and Manisha Patel

Pediatrics; originally published online May 4, 2015;
DOI: 10.1542/peds.2014-3358

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/early/2015/04/28/peds.2014-3358